BioDelivery Sciences International, Inc. (BDSI) News
Filter BDSI News Items
BDSI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BDSI News Highlights
- For BDSI, its 30 day story count is now at 21.
- Over the past 24 days, the trend for BDSI's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- COLL, DRUG and AGCO are the most mentioned tickers in articles about BDSI.
Latest BDSI News From Around the Web
Below are the latest news stories about Biodelivery Sciences International Inc that investors may wish to consider to help them evaluate BDSI as an investment opportunity.
BioDelivery Sciences launches migraine therapy in U.S.BioDelivery Sciences International (BDSI), a specialty pharmaceutical company focused on chronic conditions, announced the U.S. launch of its oral migraine therapy Elyxyb. Also known as celecoxib oral solution, Elyxyb is the first and only oral solution approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute... |
BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?Good things could be on the horizon when a stock experiences a golden cross event. How should investors react? |
BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of MigraineThe First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib |
What to Expect From Precision BioSciences (DTIL) Q4 EarningsOn Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline. |
Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & MoreMerger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week. |
Collegium to Acquire BioDelivery Sciences for $604M; Shares Up 16%Collegium Pharmaceutical, Inc. (NASDAQ: COLL) has inked a deal to acquire BioDelivery Sciences International, Inc. (NASDAQ: BDSI) in an all-cash transaction for $5.60 per share of BDSI equating to a total value of $604 million. Following the news, shares of Collegium Pharmaceutical, a leading diversified specialty pharmaceutical company, jumped 13% to close at $19.90 on February 14, and gained another 3% during the after-hours trading session. Similarly, BDSI shares gained a whopping 53% to close near the deal price at $5.56 per share. |
BioDelivery (BDSI) Stock Surges on Buyout Offer From CollegiumCollegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022. |
BDSI Stock Alert: The Deal Sending Little-Known BioDelivery Skyrocketing TodayToday, a big takeover announcement has sent shares of BioDelivery and BDSI stock soaring more than 50% on investor enthusiasm for this deal. |
Raleigh drugmaker being acquired by competitor in $604M dealA Raleigh pharmaceutical company is being acquired by a Massachusetts-based firm in a deal valued at more than $600 million. BioDelivery Sciences International (Nasdaq: BDSI) will become a wholly owned subsidiary of Collegium Pharmaceutical Inc. (Nasdaq: COLL) through a merger agreement the companies entered Monday, according to securities filings. As part of the all-cash transaction, Collegium will purchase all outstanding shares of BDSI at $5.60 per share, which is about 54 percent higher than the stock's closing price Friday of $3.64. |
Opioid maker Collegium buys N.C. competitor for $604MThe Stoughton drug company is shelling out $604 million to buy a Raleigh, N.C.-based competitor called BioDelivery Sciences International Inc. |